Pharmaceuticals, Biotechnology and Life Sciences
Pfizer and Eli lilly have announced top-line results from a Phase 3 study evaluating tanezumab 2.5mg and 5 mg.
DUBLIN–(BUSINESS WIRE)–The “Global Chemotherapy Drugs Market: Analysis By Drug Type (Antimetabolites, Plant Alkaloids, Alkylating Agents, Antitumor Antibiotics), By Administration (Oral,…
Empagliflozin, in addition to standard of care, has the potential to improve economic outcomes for people with type 2 diabetes…
Eli Lilly’s Phase 3 RELAY study of Cyramza showed improvement in the time patients lived without their cancer growing or spreading after starting treatment, the company said Tuesday.
FDA has granted Priority Review for Eli Lilly’s sBLA for Emgality (galcanezumab-gnlm) injection for the preventive treatment of episodic cluster headache in adults, the company said Tuesday in a press release.
Pfizer and Eli Lilly have been testing tanezumab in patients with moderate-to-severe chronic low back pain (CLBP) in a Phase 3 study, with certain success, as tanezumab 10 mg met the primary endpoint by reducing pain at 16 weeks compared to placebo.
Boehringer Ingelheim and Eli Lilly released the positive top-line results from the trial, which evaluated the impact of treatment with…
AstraZeneca and Eli Lilly are abandoning the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme…
Eli Lilly said Thursday its senior vice president and president of Lilly Oncology, and the member of the company’s executive…
Eli Lilly said Tuesday that the U.S. Food and Drug Administration (FDA) has approved a label update for Taltz injection 80 mg/mL to…